Cargando…

COVID-19 and SCA: an old friend comes to the rescue

Detalles Bibliográficos
Autor principal:	Novelli, Enrico M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2020
Materias:	Clinical Trials and Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256362/ https://www.ncbi.nlm.nih.gov/pubmed/32463890 http://dx.doi.org/10.1182/blood.2020006442

Ejemplares similares

Convalescent plasma to treat COVID-19
por: Bloch, Evan M.
Publicado: (2020)

COVID-19, plasma, and hypogammaglobulinemia
por: Murphy, Michael F., et al.
Publicado: (2020)

When CLL meets COVID-19
por: Montserrat, Emili
Publicado: (2020)

Vaccinations in CLL: implications for COVID-19
por: Shadman, Mazyar, et al.
Publicado: (2021)

COVID-19 and blood cancer in the vaccination era
por: Hicks, Lisa K., et al.
Publicado: (2022)

Outcomes of COVID-19 in patients with CLL: a multicenter international experience
por: Mato, Anthony R., et al.
Publicado: (2020)

The association of ABO blood group with indices of disease severity and multiorgan dysfunction in COVID-19
por: Hoiland, Ryan L., et al.
Publicado: (2020)

Comorbidities are risk factors for hospitalization and serious COVID-19 illness in children and adults with sickle cell disease
por: Mucalo, Lana, et al.
Publicado: (2021)

Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey
por: Pagano, Livio, et al.
Publicado: (2022)

Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients
por: Haggenburg, Sabine, et al.
Publicado: (2022)

Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection
por: Minniti, Caterina P., et al.
Publicado: (2021)

A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study
por: Visco, Carlo, et al.
Publicado: (2022)

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma
por: Perry, C., et al.
Publicado: (2021)

Patients with CLL have a lower risk of death from COVID-19 in the Omicron era
por: Niemann, Carsten U., et al.
Publicado: (2022)

Circulating SARS-CoV-2(+) megakaryocytes are associated with severe viral infection in COVID-19
por: Fortmann, Seth D., et al.
Publicado: (2023)

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
por: Vijenthira, Abi, et al.
Publicado: (2020)

Heterogeneous NLRP3 inflammasome signature in circulating myeloid cells as a biomarker of COVID-19 severity
por: Courjon, Johan, et al.
Publicado: (2021)

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
por: Herishanu, Yair, et al.
Publicado: (2021)

Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination
por: Herishanu, Yair, et al.
Publicado: (2022)

Under COVID of the night
por: Sekeres, Mikkael A.
Publicado: (2020)

Anti-CD19 CAR T-cell consolidation therapy combined with CD19(+) feeding T cells and TKI for Ph(+) acute lymphoblastic leukemia
por: Chen, Li-Yun, et al.
Publicado: (2023)

Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy
por: Wudhikarn, Kitsada, et al.
Publicado: (2022)

Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma
por: Roddie, Claire, et al.
Publicado: (2023)

A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial
por: Othman, Jad, et al.
Publicado: (2023)

TCRαβ/CD19 depleted HSCT from an HLA-haploidentical relative to treat children with different nonmalignant disorders
por: Merli, Pietro, et al.
Publicado: (2022)

CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany
por: Bader, Peter, et al.
Publicado: (2023)

Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
por: van Doesum, Jaap A., et al.
Publicado: (2023)

Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies
por: Davids, Matthew S., et al.
Publicado: (2021)

Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia
por: Wallace, Danielle S., et al.
Publicado: (2023)

CNS involvement in AML at diagnosis is rare and does not affect response or survival: data from 11 ECOG-ACRIN trials
por: Ganzel, Chezi, et al.
Publicado: (2021)

Long-term survival with sickle cell disease: a nationwide cohort study of Medicare and Medicaid beneficiaries
por: Jiao, Boshen, et al.
Publicado: (2023)

Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials
por: Shimony, Shai, et al.
Publicado: (2023)

Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia
por: Shimony, Shai, et al.
Publicado: (2022)

Tracking the progeny of adoptively transferred virus-specific T cells in patients posttransplant using TCR sequencing
por: Huisman, W., et al.
Publicado: (2022)

A feasibility randomized controlled trial of an mHealth app vs booklets for patient-facing guidelines in adults with SCD
por: Cronin, Robert M., et al.
Publicado: (2023)

A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial
por: Fox, Christopher P., et al.
Publicado: (2021)

Orthopedic toxicities among adolescents and young adults treated in DFCI ALL Consortium Trials
por: Valtis, Yannis K., et al.
Publicado: (2021)

Hematologic complications with age in Shwachman-Diamond syndrome
por: Furutani, Elissa, et al.
Publicado: (2022)

Diminished humoral and cellular responses to SARS-CoV-2 vaccines in patients with chronic lymphocytic leukemia
por: Ujjani, Chaitra, et al.
Publicado: (2022)

A real-world study of combined modality therapy for early-stage Hodgkin lymphoma: too little treatment impacts outcome
por: Chohan, Karan L., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_d271i9ikppo6gd0o8brlm2b8b1